Myco/Pfizer $50 mil. antifungal drugs R&D agreement is Myco's first major alliance.
Executive Summary
MYCO/PFIZER $50 MIL. ANTIFUNGAL R&D COLLABORATION IS EXCLUSIVE for human antifungal drug products, Cambridge, Mass.-based Myco Pharmaceuticals announced March 23. Pfizer will provide Myco with $20 mil. in an equity investment and R&D support over four years, and will make milestone payments that "could exceed $30 mil. if more than one drug is developed," Myco said. The strategic alliance is Myco's biggest deal since the biotech firm's genesis in 1992.